{
    "hands_on_practices": [
        {
            "introduction": "Effective medication reconciliation and deprescribing begins with a foundational skill: constructing a Best Possible Medication History (BPMH). This process is far more than a simple checklist; it is clinical detective work that requires synthesizing information from multiple, often conflicting, sources. This practice challenges you to design a systematic protocol for a complex patient scenario, reinforcing the importance of using tools like the Prescription Drug Monitoring Program (PDMP) to create an accurate medication list before any clinical decisions are made .",
            "id": "4869311",
            "problem": "A 58-year-old man with chronic obstructive pulmonary disease (COPD), chronic low back pain, generalized anxiety disorder, and hypertension is admitted for an acute COPD exacerbation. His electronic health record (EHR) medication list includes tiotropium, albuterol inhaler, lisinopril, sertraline, and hydrocodone-acetaminophen as needed. In a structured intake interview, he reports using a national chain pharmacy near his workplace for most prescriptions but sometimes using a neighborhood independent pharmacy near home. He volunteers that he has occasionally paid cash for “a few” fills of his pain medication “to avoid insurance hassles.” He lives near a state border and occasionally works across the line. There is no recent primary care follow-up note reconciling medications. The admitting team is tasked with completing a Best Possible Medication History (BPMH) and initiating deprescribing where appropriate.\n\nYou are asked to select the most appropriate protocol to achieve a BPMH that maximizes detection of potential undisclosed controlled substance fills paid in cash, while respecting typical legal and ethical constraints and creating a pragmatic workflow for internal medicine admission. Use the following foundational facts and definitions:\n\n- Best Possible Medication History (BPMH) is defined as the most accurate medication history achievable by using multiple sources, including a structured patient interview and at least one additional reliable source, such as medication containers, pharmacy fill records, and the Prescription Drug Monitoring Program (PDMP), to reconcile medication names, doses, routes, frequencies, indications, prescribers, and fill dates.\n- The Prescription Drug Monitoring Program (PDMP) is a state-run database that collects dispensings of controlled substances from pharmacies and some dispensers, typically regardless of payment source; cash transactions are expected to be reported. Many states enable interstate data sharing such that clinicians can query more than one jurisdiction when treating a patient who may cross state lines, subject to state law and institutional policy.\n- Insurance claims databases and EHR medication lists may omit cash transactions, out-of-network pharmacies, and recent fills not yet adjudicated; pharmacy dispensing records may be siloed across chains and independents.\n- A urine drug screen (UDS) detects presence of some substances with variable windows of detection and cannot reliably reconstruct a complete medication list, doses, or fill patterns; false positives and negatives occur and UDS is not a substitute for BPMH.\n- Ethical deprescribing requires identification of current medications, assessment of indication, benefit-risk balance, and patient-centered planning; abrupt discontinuation of opioids or benzodiazepines without assessment can cause harm.\n\nWhich protocol is most appropriate to achieve the stated goal?\n\nA. Rely on the EHR medication list, then conduct a brief patient interview to confirm names and doses. Call the preferred chain pharmacy only to verify last fill dates. Query the PDMP only if the patient provides explicit consent; do not inventory bottles to avoid privacy concerns. Reconcile and proceed to deprescribe any controlled substances not on the chain pharmacy’s profile.\n\nB. Perform a standardized BPMH workflow that includes: a structured, open-ended patient interview; a “brown-bag” review of all medication containers with visual inspection of labels for pharmacy, prescriber, strength, and fill dates; proactive calls to all pharmacies identified in the interview and in prior records to obtain dispensing histories for the past 12 months; querying the PDMP for the home state and, if available and applicable, neighboring state(s) through interstate data sharing, irrespective of insurance or cash payment; cross-checking for duplicate or overlapping controlled substance fills; and contemporaneous documentation of discrepancies with source attribution. If discrepancies suggesting undisclosed controlled substance use are found, notify the attending prescriber, calculate morphine milligram equivalents (MME) as needed, and initiate a patient-centered risk-benefit discussion to plan safe continuation, tapering, or substitution, with monitoring.\n\nC. Export insurance claims data for the past 6 months and reconcile with the EHR list. If these sources match, accept the list as complete. Assume that cash transactions are not relevant because they are not on insurance, and thus a PDMP query is unnecessary. Proceed to deprescribe controlled substances that are not supported by a recent claim.\n\nD. Order a comprehensive UDS and base the BPMH on laboratory results, using detected substances to infer active prescriptions and doses. Do not contact pharmacies or query the PDMP because laboratory data are objective. Use the UDS to guide deprescribing decisions.\n\nE. Ask the family to bring all medications to the bedside and discard duplicates. Avoid querying the PDMP to prevent potential legal liability. On admission, discontinue all controlled substances to eliminate risk, and consider restarting them later only if withdrawal occurs or pain is uncontrolled.",
            "solution": "The user has provided a clinical scenario and a set of foundational facts and definitions, asking for the selection of the most appropriate protocol for creating a Best Possible Medication History (BPMH) and initiating deprescribing. The primary goal is to maximize the detection of potential undisclosed controlled substance fills paid in cash.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- Patient: 58-year-old male with COPD, chronic low back pain, generalized anxiety disorder, hypertension, admitted for a COPD exacerbation.\n- EHR Medication List: Tiotropium, albuterol inhaler, lisinopril, sertraline, hydrocodone-acetaminophen as needed.\n- Patient History: Uses a national chain pharmacy and a local independent pharmacy. Has paid cash for pain medication fills. Lives near a state border and works across it. No recent primary care medication reconciliation.\n- Task: Complete a BPMH to maximize detection of undisclosed controlled substance fills and initiate deprescribing. The protocol must be pragmatic, legal, and ethical.\n- Foundational Facts and Definitions:\n    1.  **BPMH:** Requires a structured patient interview plus at least one additional reliable source (e.g., medication containers, pharmacy records, PDMP).\n    2.  **PDMP:** State-run database tracking controlled substance dispensings, including cash transactions. Interstate data sharing is often available.\n    3.  **Data Source Limitations:** EHRs and insurance claims are incomplete, often missing cash transactions and out-of-network fills.\n    4.  **UDS Limitations:** A urine drug screen (UDS) is not a substitute for a BPMH, as it cannot confirm doses, frequencies, or fill patterns.\n    5.  **Ethical Deprescribing:** Requires a full medication assessment and patient-centered planning; abrupt discontinuation of certain substances can cause harm.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is valid. It presents a realistic and complex clinical scenario that is common in internal medicine. The task is well-defined, with a clear objective and a set of constraints. The \"foundational facts\" provide a consistent, scientifically grounded framework for evaluating the options, effectively acting as axioms for the problem. The scenario is free of contradictions, scientific inaccuracies, or subjective claims. It is a well-posed problem in clinical decision-making.\n\n**Step 3: Verdict and Action**\nThe problem is valid. I will proceed to derive the solution and evaluate the options.\n\n### Solution Derivation\n\nThe stated goal is to select a protocol that *maximizes detection* of undisclosed controlled substance use, which, in this patient's case, is suggested by his use of multiple pharmacies, cash payments, and cross-border activity. The optimal protocol must therefore utilize the most effective tools for uncovering this specific information, as described by the provided foundational facts.\n\n1.  A \"Best Possible Medication History\" by definition requires using multiple sources beyond just the patient interview.\n2.  The Prescription Drug Monitoring Program (PDMP) is defined as the key tool for tracking controlled substances, `regardless of payment source`. This makes it essential for detecting cash fills. The availability of interstate data sharing makes it the ideal tool for a patient who crosses state lines.\n3.  The patient's own medication containers (\"brown-bag\" review) and direct calls to all identified pharmacies are also defined as reliable sources.\n4.  Insurance claims and EHR lists are explicitly defined as potentially incomplete.\n5.  A UDS is explicitly defined as an inadequate substitute for a BPMH.\n6.  Ethical deprescribing explicitly forbids the abrupt discontinuation of opioids without a proper assessment and plan.\n\nThe most appropriate protocol must therefore be comprehensive, leveraging a structured interview, a review of physical medications, calls to all known pharmacies, and, critically, a multi-state PDMP query. Any subsequent action based on discovered discrepancies must be patient-centered and prioritize safety over punitive measures.\n\n### Option-by-Option Analysis\n\n**A. Rely on the EHR medication list, then conduct a brief patient interview to confirm names and doses. Call the preferred chain pharmacy only to verify last fill dates. Query the PDMP only if the patient provides explicit consent; do not inventory bottles to avoid privacy concerns. Reconcile and proceed to deprescribe any controlled substances not on the chain pharmacy’s profile.**\n\n**Analysis:** This protocol is patently inadequate. It relies on a \"brief\" interview and incomplete data sources (only one pharmacy). It avoids a \"brown-bag\" review of medication bottles, discarding a key source of information. It makes the PDMP query, the single most important tool for the stated goal, contingent and potentially omits it. Most critically, its plan to \"deprescribe any controlled substances not on the chain pharmacy’s profile\" is based on incomplete data and represents an unsafe, abrupt discontinuation, directly contradicting the definition of ethical deprescribing.\n**Verdict:** **Incorrect**.\n\n**B. Perform a standardized BPMH workflow that includes: a structured, open-ended patient interview; a “brown-bag” review of all medication containers with visual inspection of labels for pharmacy, prescriber, strength, and fill dates; proactive calls to all pharmacies identified in the interview and in prior records to obtain dispensing histories for the past 12 months; querying the PDMP for the home state and, if available and applicable, neighboring state(s) through interstate data sharing, irrespective of insurance or cash payment; cross-checking for duplicate or overlapping controlled substance fills; and contemporaneous documentation of discrepancies with source attribution. If discrepancies suggesting undisclosed controlled substance use are found, notify the attending prescriber, calculate morphine milligram equivalents (MME) as needed, and initiate a patient-centered risk-benefit discussion to plan safe continuation, tapering, or substitution, with monitoring.**\n\n**Analysis:** This protocol is the gold standard and directly aligns with all the foundational facts. It employs multiple reliable sources (structured interview, brown-bag review, all identified pharmacies, multi-state PDMP query), which is the definition of a BPMH. It specifically utilizes the PDMP to address the risks of multiple pharmacies, cash payments, and cross-border activity, thus maximizing the chance of detection. The follow-up actions (calculating MME, patient-centered discussion, safe tapering/continuation) are the epitome of the ethical and evidence-based management of opioid use, avoiding the harm of abrupt discontinuation.\n**Verdict:** **Correct**.\n\n**C. Export insurance claims data for the past 6 months and reconcile with the EHR list. If these sources match, accept the list as complete. Assume that cash transactions are not relevant because they are not on insurance, and thus a PDMP query is unnecessary. Proceed to deprescribe controlled substances that are not supported by a recent claim.**\n\n**Analysis:** This protocol is built on a false premise. The foundational facts state that insurance claims data may omit cash transactions, and the patient admitted to paying with cash. Assuming cash transactions are \"not relevant\" is a direct contradiction of the problem's context and goal. Avoiding the PDMP query guarantees failure in detecting the undisclosed fills. This method does not constitute a BPMH.\n**Verdict:** **Incorrect**.\n\n**D. Order a comprehensive UDS and base the BPMH on laboratory results, using detected substances to infer active prescriptions and doses. Do not contact pharmacies or query the PDMP because laboratory data are objective. Use the UDS to guide deprescribing decisions.**\n\n**Analysis:** This protocol misinterprets the utility of a UDS. The foundational facts explicitly state that a UDS \"is not a substitute for BPMH\" and \"cannot reliably reconstruct a complete medication list, doses, or fill patterns.\" While objective, the data from a UDS are insufficient for creating a BPMH and cannot provide the necessary detail for safe deprescribing (e.g., dose, frequency, last fill date). Ignoring the PDMP and pharmacy records is a critical omission.\n**Verdict:** **Incorrect**.\n\n**E. Ask the family to bring all medications to the bedside and discard duplicates. Avoid querying the PDMP to prevent potential legal liability. On admission, discontinue all controlled substances to eliminate risk, and consider restarting them later only if withdrawal occurs or pain is uncontrolled.**\n\n**Analysis:** This protocol is dangerous and unethical. First, avoiding the PDMP for fear of liability is misguided; failure to use available safety tools like the PDMP often increases liability. Second, the instruction to \"discontinue all controlled substances to eliminate risk\" is medically reckless. As stated in the foundational facts, abrupt discontinuation of opioids can cause significant harm from withdrawal. This approach prioritizes a simplistic (and incorrect) view of risk mitigation over patient safety and constitutes malpractice.\n**Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Once a reliable medication list is established, the next step is to evaluate each drug's appropriateness for the individual patient. A critical component of this assessment is considering the patient's organ function, particularly renal clearance, which governs the safety of many common medications. This exercise will guide you through calculating creatinine clearance ($CrCl$) using the Cockcroft-Gault equation and applying this result to make a guideline-based deprescribing decision for metformin, a cornerstone of diabetes management .",
            "id": "4869337",
            "problem": "A hospitalized patient undergoing medication reconciliation is a 78-year-old female with Type 2 Diabetes Mellitus, currently prescribed metformin immediate-release at $1000\\,\\mathrm{mg}$ twice daily. Her recent laboratory values are stable: serum creatinine (SCr) $= 1.4\\,\\mathrm{mg/dL}$ measured on two occasions 24 hours apart with no intervening nephrotoxic exposures, and her vital statistics are body weight $= 55\\,\\mathrm{kg}$ and height $= 160\\,\\mathrm{cm}$. To guide a deprescribing decision at discharge, renal function must be quantified in a manner suitable for drug dosing. Use the Cockcroft–Gault approach to estimate creatinine clearance (CrCl) appropriate for this patient, and then normalize the result to the standard body surface area of $1.73\\,\\mathrm{m^2}$ to obtain a value consistent with the estimated Glomerular Filtration Rate (eGFR) reporting convention. Body Surface Area (BSA) normalization should be performed using a clinically standard method for BSA estimation from height and weight.\n\nFor metformin, use the following widely accepted thresholds based on normalized eGFR in $\\mathrm{mL/min/1.73\\,m^2}$:\n- Avoid and deprescribe when eGFR is $< 30$.\n- Consider dose reduction and reassess risks when eGFR is in the interval $[30,44]$.\n- Generally continue when eGFR is $\\geq 45$.\n\nDefine the binary deprescribing indicator $D$ by $D = 1$ if metformin should be deprescribed under these thresholds, and $D = 0$ otherwise. Compute the normalized eGFR value in $\\mathrm{mL/min/1.73\\,m^2}$ rounded to three significant figures, determine $D$ accordingly, and report only $D$ as the final answer (dimensionless).",
            "solution": "The problem requires the calculation of a normalized estimated Glomerular Filtration Rate (eGFR) for a patient to determine a course of action for metformin therapy. This will be done in three steps: first, calculating the creatinine clearance (CrCl) using the Cockcroft-Gault equation; second, calculating the patient's Body Surface Area (BSA); and third, normalizing the CrCl to the standard BSA of $1.73\\,\\mathrm{m^2}$ to obtain the eGFR. Finally, this eGFR value will be compared against the provided thresholds to determine the binary deprescribing indicator, $D$.\n\nThe patient's given parameters are:\n- Age ($A$): $78$ years\n- Sex: Female\n- Body Weight ($W$): $55\\,\\mathrm{kg}$\n- Height ($H$): $160\\,\\mathrm{cm}$\n- Serum Creatinine (SCr): $1.4\\,\\mathrm{mg/dL}$\n\nFirst, we apply the Cockcroft-Gault formula to estimate the unnormalized creatinine clearance. The general formula is:\n$$\n\\text{CrCl} = \\frac{(140 - A) \\times W}{72 \\times \\text{SCr}}\n$$\nwhere CrCl is in $\\mathrm{mL/min}$, age $A$ is in years, weight $W$ is in $\\mathrm{kg}$, and SCr is in $\\mathrm{mg/dL}$. For female patients, the result is multiplied by a correction factor of $0.85$.\nSubstituting the patient's values:\n$$\n\\text{CrCl} = \\frac{(140 - 78) \\times 55}{72 \\times 1.4} \\times 0.85\n$$\n$$\n\\text{CrCl} = \\frac{62 \\times 55}{100.8} \\times 0.85 = \\frac{3410}{100.8} \\times 0.85\n$$\n$$\n\\text{CrCl} \\approx (33.829365...) \\times 0.85 \\approx 28.75496...\\,\\mathrm{mL/min}\n$$\n\nSecond, we calculate the patient's Body Surface Area (BSA) to use for normalization. A clinically standard method is the Mosteller formula:\n$$\n\\text{BSA} = \\sqrt{\\frac{H \\times W}{3600}}\n$$\nwhere BSA is in $\\mathrm{m^2}$, height $H$ is in $\\mathrm{cm}$, and weight $W$ is in $\\mathrm{kg}$.\nSubstituting the patient's values:\n$$\n\\text{BSA} = \\sqrt{\\frac{160 \\times 55}{3600}} = \\sqrt{\\frac{8800}{3600}} = \\sqrt{\\frac{22}{9}} = \\frac{\\sqrt{22}}{3}\n$$\n$$\n\\text{BSA} \\approx 1.563472...\\,\\mathrm{m^2}\n$$\n\nThird, we normalize the calculated CrCl to the standard BSA of $1.73\\,\\mathrm{m^2}$. This normalized value is treated as the eGFR for the purpose of applying the given thresholds.\n$$\n\\text{eGFR} = \\text{CrCl} \\times \\frac{1.73\\,\\mathrm{m^2}}{\\text{BSA}}\n$$\nSubstituting the calculated values for CrCl and BSA:\n$$\n\\text{eGFR} \\approx 28.75496\\,\\mathrm{mL/min} \\times \\frac{1.73\\,\\mathrm{m^2}}{1.563472\\,\\mathrm{m^2}}\n$$\n$$\n\\text{eGFR} \\approx 31.8159...\\,\\mathrm{mL/min/1.73\\,m^2}\n$$\nThe problem specifies rounding this value to three significant figures, which yields $31.8\\,\\mathrm{mL/min/1.73\\,m^2}$.\n\nFinally, we determine the deprescribing indicator $D$. The problem defines the conditions as:\n- Avoid and deprescribe when eGFR is $< 30\\,\\mathrm{mL/min/1.73\\,m^2}$.\n- Consider dose reduction and reassess risks when eGFR is in the interval $[30, 44]\\,\\mathrm{mL/min/1.73\\,m^2}$.\n- Generally continue when eGFR is $\\geq 45\\,\\mathrm{mL/min/1.73\\,m^2}$.\n\nThe binary indicator $D$ is defined as $D=1$ if metformin should be deprescribed, and $D=0$ otherwise. According to the stated rules, \"deprescribing\" is the action for eGFR $< 30$. Our calculated eGFR is $31.8$.\nWe check the condition for $D=1$:\n$$\n31.8 < 30\n$$\nThis is false. The patient's eGFR falls into the range $[30, 44]$, for which the recommended action is to consider dose reduction and reassess, not to deprescribe. Therefore, the condition for setting $D=1$ is not met.\n\nThus, the deprescribing indicator $D$ is $0$.",
            "answer": "$$\\boxed{0}$$"
        },
        {
            "introduction": "Beyond assessing individual drugs, effective deprescribing requires evaluating the cumulative risk of a patient's entire regimen. Certain medication classes, like those with anticholinergic properties, can have additive negative effects, particularly on cognition in older adults. This practice introduces the Anticholinergic Cognitive Burden (ACB) scale, a validated tool to quantify this risk, and allows you to calculate the direct impact of thoughtful substitutions on reducing a patient's overall medication burden .",
            "id": "4869369",
            "problem": "A hospitalized patient in internal medicine is undergoing medication reconciliation and deprescribing. The patient is a 76-year-old adult with Type 2 diabetes mellitus, painful distal symmetric polyneuropathy, overactive bladder with urge urinary incontinence, and chronic insomnia. The current home regimen includes amitriptyline $25\\,\\mathrm{mg}$ nightly (for neuropathic pain and sleep), oxybutynin extended-release $10\\,\\mathrm{mg}$ daily (for overactive bladder), and diphenhydramine $50\\,\\mathrm{mg}$ nightly (for insomnia). The patient reports dry mouth, constipation, and recent difficulty with attention and short-term memory.\n\nThe Anticholinergic Cognitive Burden (ACB) is a validated clinical tool that assigns a categorical score reflecting anticholinergic activity to each drug, and the total regimen burden is obtained by summing drug-specific scores. Using widely accepted ACB classifications, assume amitriptyline has ACB score $3$, oxybutynin has ACB score $3$, and diphenhydramine has ACB score $3$. For deprescribing, propose and implement substitutions with lower anticholinergic activity: replace amitriptyline with duloxetine $30\\,\\mathrm{mg}$ daily for neuropathic pain (ACB score $0$), replace oxybutynin with mirabegron $25\\,\\mathrm{mg}$ daily for overactive bladder (ACB score $0$), and replace diphenhydramine with melatonin $2\\,\\mathrm{mg}$ nightly for insomnia (ACB score $0$).\n\nBased on these assumptions, compute the absolute reduction in the total ACB score that results from implementing the proposed substitutions. Express your final answer as a single unitless number. No rounding is necessary.",
            "solution": "The problem requires the computation of the absolute reduction in the total Anticholinergic Cognitive Burden (ACB) score for a patient undergoing medication changes. The problem is validated as scientifically grounded, well-posed, and objective. The clinical scenario, drugs, and the ACB scoring system are standard in the field of internal and geriatric medicine. All necessary data for the calculation are provided.\n\nFirst, we must calculate the total initial ACB score, which we will denote as $S_{initial}$. The problem states that the total regimen burden is the sum of the drug-specific scores. The patient's initial regimen consists of three medications: amitriptyline, oxybutynin, and diphenhydramine.\n\nThe given ACB scores for the initial medications are:\n- Amitriptyline: $ACB_{amitriptyline} = 3$\n- Oxybutynin: $ACB_{oxybutynin} = 3$\n- Diphenhydramine: $ACB_{diphenhydramine} = 3$\n\nThe total initial score, $S_{initial}$, is the sum of these individual scores:\n$$S_{initial} = ACB_{amitriptyline} + ACB_{oxybutynin} + ACB_{diphenhydramine}$$\n$$S_{initial} = 3 + 3 + 3 = 9$$\n\nNext, we must calculate the total final ACB score, denoted as $S_{final}$, after the proposed substitutions are implemented. The deprescribing plan involves replacing each of the initial medications with a new one.\n\nThe proposed new medications and their given ACB scores are:\n- Duloxetine (replaces amitriptyline): $ACB_{duloxetine} = 0$\n- Mirabegron (replaces oxybutynin): $ACB_{mirabegron} = 0$\n- Melatonin (replaces diphenhydramine): $ACB_{melatonin} = 0$\n\nThe total final score, $S_{final}$, is the sum of the scores of the new medications:\n$$S_{final} = ACB_{duloxetine} + ACB_{mirabegron} + ACB_{melatonin}$$\n$$S_{final} = 0 + 0 + 0 = 0$$\n\nThe problem asks for the absolute reduction in the total ACB score. This is the difference between the initial total score and the final total score. Let this reduction be denoted by $\\Delta S$.\n$$\\Delta S = S_{initial} - S_{final}$$\n\nSubstituting the calculated values for $S_{initial}$ and $S_{final}$:\n$$\\Delta S = 9 - 0$$\n$$\\Delta S = 9$$\n\nThe absolute reduction in the total ACB score is $9$. The problem specifies a single unitless number as the answer.",
            "answer": "$$\\boxed{9}$$"
        }
    ]
}